Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Нервные болезни
2021 / N 1

Современные возможности применения a-липоевой кислоты
П.Р. Камчатнов, А.В. Чугунов

References

1. Zimmet P, Alberti KG, Magliano DJ, Bennett PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nature Reviews. Endocrinology 2016 Oct;12(10):616-22.
2. Qin P, Liu D, Wu X, Zeng Y, Sun X, Zhang Y, Li Y, Wu Y, Han M, Qie R, Huang S, Zhao Y, Feng Y, Yang X, Liu Y, Li H, Zhang M, Hu D, Hu F. Fried-food consumption and risk of overweight/obesity, type 2 diabetes mellitus, and hypertension in adults: a meta-analysis of observational studies. Critical Reviews in Food Science and Nutrition 2021 Apr 7;1-12. doi: 10.1080/10408398.2021.1906626. Online ahead of print.
3. Yerramalla MS, Fayosse A, Dugravot A, Tabak AG, Kivimäki M, Singh-Manoux A, Sabia S. Association of moderate and vigorous physical activity with incidence of type 2 diabetes and subsequent mortality: 27 year follow-up of the Whitehall II study. Diabetologia 2020 Mar;63(3):537-48.
4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004 May;27(5):1047-53.
5. Zhou J, Lee S, Wang X, Li Y, Wu WKK, Liu T, Cao Z, Zeng DD, Leung KSK, Wai AKC, Wong ICW, Cheung BMY, Zhang Q, Tse G. Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong. NPJ Digital Medicine 2021 Apr;4(1):66.
6. Mizukami H, Osonoi S. Pathogenesis and molecular treatment strategies of diabetic neuropathy collateral glucose-utilizing pathways in diabetic polyneuropathy. International Journal of Molecular Science 2020 Dec;22(1):94.
7. Lan D, Jiang H, Su X, Zhao Y, Du S, Li Y, Bi R, Zhang DF, Yang Q. Transcriptome-wide association study identifies genetically dysregulated genes in diabetic neuropathy. Combinatorial Chemistry & High Throughput Screening 2021;24(2):319-25.
8. Galosi E, Di Pietro G, La Cesa S, Di Stefano G, Leone C, Fasolino A, Di Lionardo A, Leonetti F, Buzzetti R, Mollica C, Cruccu G, Truini A. Differential involvement of myelinated and unmyelinated nerve fibers in painful diabetic polyneuropathy. Muscle & Nerve 2021 Jan;63(1):68-74.
9. Rojas DR, Tegeder I, Kuner R, Agarwal N. Hypoxia-inducible factor 1α protects peripheral sensory neurons from diabetic peripheral neuropathy by suppressing accumulation of reactive oxygen species. Journal of Molecular Medicine (Berlin, Germany) 2018 Dec;96(12):1395-405.
10. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacology & Therapeutics 2008 Oct;120(1):1-34.
11. Russell J, Zilliox L. Diabetic neuropathies. Continuum (Minneapolis, Minn.) 2014 Oct;20(5 Peripheral Nervous System Disorders):1226-40.
12. Jensen TS, Karlsson P, Gylfadottir SS, Andersen ST, Bennett DL, Tankisi H, Finnerup NB, Terkelsen AJ, Khan K, Themistocleous AC, Kristensen AG, Itani M, Sindrup SH, Andersen H, Charles M, Feldman EL, Callaghan BC. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain 2021 Mar 12:awab079. doi: 10.1093/brain/awab079. Epub ahead of print. PMID: 33711103.
13. Al Olaiwi LA, Al Harbi TJ, Tourkmani AM. Prevalence of cardiovascular autonomic neuropathy and gastroparesis symptoms among patients with type 2 diabetes who attend a primary health care center. PLoS One 2018 Dec;13(12):e0209500.
14. Atri A, Kocherlakota C, Dasgupta R. Managing diabetic foot in times of COVID-19: time to put the best ‘foot’ forward. International Journal of Diabetes in Developing Countries 2020 Sep 1;1-8. doi: 10.1007/s13410-020-00866-9. Online ahead of print.
15. Camdessanche JP, Morel J, Pozzetto B, Paul S, Tholance Y, Botelho-Nevers E. COVID-19 may induce Guillain–Barré syndrome. Revue Neurologique (Paris) 2020 Jun;176(6):516-8.
16. Zhao H, Shen D, Zhou H, Liu J, Chen S. Guillain–Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? The Lancet. Neurology 2020 May;19(5):383-4.
17. Odriozola A, Ortega L, Martinez L, Odriozola S, Torrens A, Corroleu D, Martínez S, Ponce M, Meije Y, Presas M, Duarte A, Odriozola MB, Malik RA. Widespread sensory neuropathy in diabetic patients hospitalized with severe COVID-19 infection. Diabetes Research and Clinical Practice 2021 Feb;172:108631. Published online 2020 Dec 17.
18. Chen D, Zhou H, Yang Y, Zhang Y, Xie C. The adverse effects of novel coronavirus on diabetic foot patients: a protocol for systematic review and meta analysis. Medicine (Baltimore) 2020 Oct 23;99(43):e22758.
19. Pitocco D, Viti L, Santoliquido A, Tartaglione L, Di Leo M, Bianchi A, Caputo S, Pontecorvi A. Diabetic neuropathy: a risk factor for severe COVID-19? Acta Diabetologica 2021 Feb 3;1-2. doi: 10.1007/s00592-020-01658-7. Online ahead of print.
20. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of immune response in patients with COVID-19 in Wuhan China. Clinical Infectious Diseases 2020 Jul;71(15):762-8.
21. Tracey KJ. The inflammatory reflex. Nature 2002 Dec 19-26;420(6917):853-9.
22. Pitocco D, Santangeli P, Fuso L, Zaccardi Z, Longobardi A, Infusino F, Incalzi RA, Lanza GA, Crea F, Ghirlanda G. Association between reduced pulmonary diffusing capacity and cardiac autonomic dysfunction in type 1 diabetes. Diabetic Medicine 2008 Nov;25(11):1366-9.
23. Pitocco D, Fuso L, Conte EG, Zaccardi F, Condoluci C, Scavone G, Incalzi RA, Ghirlanda G. The diabetic lung – a new target organ? The Review of Diabetic Studies 2012 Spring;9(1):23-35.
24. Ziegler D, Papanas N, Schnell O, Nguyen BDT, Nguyen KT, Kulkantrakorn K, Deerochanawong C. Current concepts in the management of diabetic polyneuropathy. Journal of Diabetes Investigation 2021 Apr;12(4):464-75.
25. Ardeleanu V, Toma A, Pafili K, Papanas N, Motofei I, Diaconu CC, Rizzo M, Stoian AP. Current pharmacological treatment of painful diabetic neuropathy: a narrative review. Medicina (Kaunas, Lithuania) 2020 Jan;56(1):25-32.
26. Rochette L, Ghibu S, Muresan A, Vergely C. Alpha-lipoic acid: molecular mechanisms and therapeutic potential in diabetes. Canadian Journal of Physiology and Pharmacology 2015 Dec;93(12):1021-7.
27. Ansar H, Mazloom Z, Kazemi F, Hejazi N. Effect of alpha-lipoic acid on blood glucose, insulin resistance and glutathione peroxidase of type 2 diabetic patients. Saudi Medical Journal 2011 Jun;32(6):584-8.
28. Le Garf S, Sibille B, Mothe-Satney I, Eininger C, Fauque P, Murdaca J, Chinetti G, Neels JG, Rousseau AS. Alpha-lipoic acid supplementation increases the efficacy of exercise- and diet-induced obesity treatment and induces immunometabolic changes in female mice and women. FASEB Journal 2021 Apr;35(4):e21312.
29. Derosa G, D’Angelo A, Romano D, Maffioli P. A clinical trial about a food supplement containing α-lipoic acid on oxidative stress markers in type 2 diabetic patients. International Journal of Molecular Sciences 2016 Oct;17(11):1802.
30. Scaramuzza A, Giani E, Redaelli F, Ungheri S, Macedoni M, Giudici V, Bosetti A, Ferrari M, Zuccotti GV. Alpha-lipoic acid and antioxidant diet help to improve endothelial dysfunction in adolescents with type 1 diabetes: a pilot trial. Journal of Diabetes Research 2015;2015:474561.
31. Himeno T, Kamiya H, Nakamura J. Diabetic polyneuropathy: progress in diagnostic strategy and novel target discovery, but stagnation in drug development. Journal of Diabetes Investigation 2020 Jan;11(1):25-7.
32. Sun LQ, Chen YY, Wang X, Li XL, Xue B, Qu L, Zhang TT, Mu YM, Lu JM. The protective effect of alpha lipoic acid on Schwann cells exposed to constant or intermittent high glucose. Biochemical Pharmacology 2012 Oct;84(7):961-73.
33. Gomes MB, Negrato CA. Alpha-lipoic acid as a pleiotropic compound with potential therapeutic use in diabetes and other chronic diseases. Diabetology & Metabolic Syndrome 2014 Jul;6(1):80.
34. Suzuki YJ, Aggarwal BB, Packer L. Alpha-lipoic acid is a potent inhibitor of NF-κB activation in human T cells. Biochemical and Biophysical Research Communications 1992;189(3):1709-15.
35. Liao BC, Hsieh CW, Lin YC, Wung BS. The glutaredoxin/glutathione system modulates NF-κB activity by glutathionylation of p65 in cinnamaldehyde-treated endothelial cells. Toxicological Sciences 2010 Jul;116(1):151-63.
36. Konrad T, Vicini P, Kusterer K, Höflich A, Assadkhani A, Böhles HJ, Sewell A, Tritschler HJ, Cobelli C, Usadel KH. Alpha-lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22(2):280-7.
37. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schütte K, Kerum G, Malessa R. Treatment of symptomatic diabetic peripheral neuropathy with antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999 Aug;22(8):1296-301.
38. Ziegler D, Ametov A, Barinov A, Dyck PJ, Gurieva I, Low PA, Munzel U, Yakhno N, Raz I, Novosadova M, Maus J, Samigullin R. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy. The SYDNEY 2 trial. Diabetes Care 2006 Nov;29(11):2365-70.
39. Pavlov NA, Stakhovskaya LV, Gekht AB, Kovrazhkina EA, Ayriyan NYu, Serkin GV, Glushkov KS, Skvortsova VI. Berlithione in treatment of alcoholic polyneuropathy. SS Korsakov Journal of Neurology and Psychiatry 2004;104(2):33-7 (In Russian).
40. Kovrazhkina EA. Demyelinating polyneuropathies in patients with diabetes mellitus and chronic alcohol intoxication. SS Korsakov Journal of Neurology and Psychiatry 2012;112(5):41-5 (In Russian).
41. Ziegler D, Low PA, Litchy W, Boulton AJM, Vinik AI, Freeman R, Samigullin R, Tritschler H, Munzel U, Maus J, Schütte K, Dyck PJ. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011 Sep;34(9):2054-60.
42. Spisakova M, Cizek Z, Melkova Z. Ethacrynic and alpha-lipoic acids inhibit vaccinia virus late gene expression. Antiviral Research 2009 Feb;81(2):156-65.
43. Zhang L, Liu Y. Potential interventions for novel coronavirus in China: a systematic review. Journal of Medical Virology 2020 May;92(5):479-90.
44. Zhong M, Sun A, Xiao T, Yao G, Sang L, Zheng X, Zhang J, Jin X, Xu L, Yang W, Wang P, Hu K, Zhang D, Ge J. A randomized, single-blind, group sequential, active-controlled study to evaluate the clinical efficacy and safety of α-lipoic acid for critically ill patients with coronavirus disease 2019 (COVID-19). medRxiv 2020 Apr 21.
45. Farhat D, Léon S, Ghayad SE, Gadot N, Icard P, Le Romancer M, Hussein N, Lincet H. Lipoic acid decreases breast cancer cell proliferation by inhibiting IGF-1R via furin downregulation. British Journal of Cancer 2020 Mar;122(6):885-94.
46. Pal R, Bhadada SK. Should anti-diabetic medications be reconsidered amid COVID-19 pandemic? Diabetes Research and Clinical Practice 2020 May;163:108146.
47. Dudek M, Razny K, Bilska-Wilkosz A, Iciek M, Sapa J, Wlodek L, Filipek B. Hypotensive effect of alpha-lipoic acid after a single administration in rats. The Anatolian Journal of Cardiology 2016;16(5):306-9.
48. Khramilin VN, Demidova IYu, Ignatova OYu. Efficacy of different modes of per os therapy for painful diabetic peripheral polyneuropathy with alpha-lipoic acid. Diabetes Mellitus 2010;2:28-34 (In Russian).
49. Barut EN, Engin S, Saygın I, Kaya-Yasar Y, Arici S, Sezen SF. Alpha-lipoic acid: a promising adjuvant for nonsteroidal anti-inflammatory drugs therapy with improved efficacy and gastroprotection. Drug Development Research 2021 Jan 24. doi: 10.1002/ddr.21791. Online ahead of print.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]